Advertisement
  • From the Editor-in-Chief

    Cancer in Minority Populations

    Paying attention to the social determinants of health will promote greater equity in cancer outcomes for all.

    by William G. Nelson, MD, PhD

  • Forward Look

    Creating More Inclusive Clinical Trials

    The Clinical Treatment Act aims to include more Medicaid recipients.

    by Jen Tota McGivney

  • Survivor Profile

    An Unlikely Pivot

    Medha Deoras-Sutliff’s experience with breast cancer fueled her interest in advocacy for breast cancer patients and, more recently, her support for research on rare cancers.

    by Lindsey Konkel

  • Policy Matters

    The E-Cigarette Regulatory Landscape

    The FDA is taking several steps to restrict and reduce e-cigarette use among youth.

    by Carmine S. Leggett, PhD

  • Get Involved

    Patients With Pets

    A helping hand for pet owners receiving cancer treatment.

    by Jackie Oshiro

  • Learning Medicare’s ABCDs

    Medicare was established to help provide affordable health care coverage for older Americans. But Medicare beneficiaries with cancer can still face financial burdens related to their care.

    by Kate Yandell

  • A Missed Conversation

    Despite national guidelines urging oncologists to bring up risks of infertility posed by cancer treatment, many young cancer patients are never told about these risks or counseled on their fertility preservation options.

    by Marcus A. Banks

  • In It for the Long Haul

    Doctors and researchers met online to discuss how the coronavirus pandemic changed cancer care in its early months, as well as how they can improve care and advocate for patients going forward.

    by Kate Yandell

  • The Return to Work

    What happens if your workplace reopens before you’re ready to return or you’re an essential worker? For some people who have been diagnosed with cancer, accommodations may be possible.

    by Jen Tota McGivney

  • From the Editor-In-Chief

    Measuring a Cancer Drug’s Effectiveness

    Surrogate endpoints can speed up drug approvals, but are they valid measures of effectiveness?

    by William G. Nelson, MD, PhD

Advertisement

From the AACR

  • A CAR-T Cell Therapy Pioneer

    In an interview, Carl June discusses CAR-T cell therapy, as well as his own experience with COVID-19.

  • Advances in Lymphoma

    A meeting on lymphoma covered diverse topics, ranging from immunotherapeutic strategies to advances in single-cell analyses to health disparities.

  • Cancer Disparities Progress Report

    The inaugural Cancer Disparities Progress Report highlights the urgent need to reduce cancer health disparities and achieve health equity for all people.

Advertisement

Video

Handle With Care

Advertisement

social media

donate to the AACR